Amarin (AMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...

Amarin said Peter Fishman has been appointed its new finance chief, effective immediately. The company said Fishman most recently served as its global controller and principal financial and ...

-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients 1 -- -- Italy is the Third EU5 Market to ...

Generic drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that sets up early competition to cardiovascular drug Vascepa, Amarin’s only commercial ...

Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc ...

NASDAQ:AMRN opened at $0.45 on Friday. Amarin has a twelve month low of $0.43 and a twelve month high of $1.37. The firm’s fifty day simple moving average is $0.52 and its 200 day simple moving ...

-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients1 -- -- Italy is the Third EU5 Market to ...